242 related articles for article (PubMed ID: 24393588)
41. Faecal occult blood testing screening for colorectal cancer and 'missed' interval cancers: are we ignoring the elephant in the room? Results of a multicentre study.
George AT; Aggarwal S; Dharmavaram S; Menon A; Dube M; Vogler M; Field A
Colorectal Dis; 2017 May; 19(5):O108-O114. PubMed ID: 27992095
[TBL] [Abstract][Full Text] [Related]
42. Trends and inequities in colorectal cancer screening participation in Ontario, Canada, 2005-2011.
Honein-AbouHaidar GN; Baxter NN; Moineddin R; Urbach DR; Rabeneck L; Bierman AS
Cancer Epidemiol; 2013 Dec; 37(6):946-56. PubMed ID: 23702337
[TBL] [Abstract][Full Text] [Related]
43. Impact of a population-based colorectal cancer screening program on local health services demand in Italy: a 7-year survey in a northern province.
Parente F; Marino B; Ardizzoia A; Ucci G; Ilardo A; Limonta F; Villani P; Moretti R; Zucchi A; Cremaschini M; Pirola ME
Am J Gastroenterol; 2011 Nov; 106(11):1986-93. PubMed ID: 21670773
[TBL] [Abstract][Full Text] [Related]
44. Excellent performance of Hemoccult Sensa in organised colorectal cancer screening.
Kershenbaum A; Flugelman A; Lejbkowicz F; Arad H; Rennert G
Eur J Cancer; 2013 Mar; 49(4):923-30. PubMed ID: 23099005
[TBL] [Abstract][Full Text] [Related]
45. [Feasibility of colorectal cancer screening with fecal occult blood test distributed by public pharmacies].
Pippa G; Ferrara M; Valle S; Diego B; Alessandra B; Apuzzo M; Bazuro ME; Tammaro G; Federici A
Recenti Prog Med; 2009; 100(7-8):348-51. PubMed ID: 19725474
[TBL] [Abstract][Full Text] [Related]
46. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
47. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort.
Chen LS; Yen AM; Chiu SY; Liao CS; Chen HH
Lancet Oncol; 2011 Jun; 12(6):551-8. PubMed ID: 21592859
[TBL] [Abstract][Full Text] [Related]
48. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
49. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
Quintero E
Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
[TBL] [Abstract][Full Text] [Related]
50. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds.
Kronborg O; Jørgensen OD; Fenger C; Rasmussen M
Scand J Gastroenterol; 2004 Sep; 39(9):846-51. PubMed ID: 15513382
[TBL] [Abstract][Full Text] [Related]
51. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up.
Scholefield JH; Moss SM; Mangham CM; Whynes DK; Hardcastle JD
Gut; 2012 Jul; 61(7):1036-40. PubMed ID: 22052062
[TBL] [Abstract][Full Text] [Related]
52. Gene expression analysis using a highly sensitive DNA microarray for colorectal cancer screening.
Koga Y; Yamazaki N; Takizawa S; Kawauchi J; Nomura O; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y
Anticancer Res; 2014 Jan; 34(1):169-76. PubMed ID: 24403458
[TBL] [Abstract][Full Text] [Related]
53. Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening.
DeBourcy AC; Lichtenberger S; Felton S; Butterfield KT; Ahnen DJ; Denberg TD
J Gen Intern Med; 2008 Feb; 23(2):169-74. PubMed ID: 18157581
[TBL] [Abstract][Full Text] [Related]
54. [Necessity and feasibility of screening for colorectal cancer in China].
Zhang SZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2011 Jan; 14(1):16-8. PubMed ID: 21271373
[TBL] [Abstract][Full Text] [Related]
55. [Results of the Czech National Colorectal Cancer screening programme - faecal occult blood tests].
Seifert B; Májek O; Zavoral M; Král N; Suchánek S; Ngo O; Dušek L
Klin Onkol; 2014; 27 Suppl 2():87-97. PubMed ID: 25494893
[TBL] [Abstract][Full Text] [Related]
56. Impact of faecal occult blood test screening on emergency admissions and short-term outcomes for colorectal cancer.
Libby G; Brewster DH; Steele RJ
Br J Surg; 2014 Nov; 101(12):1607-15. PubMed ID: 25219923
[TBL] [Abstract][Full Text] [Related]
57. Use of lower gastrointestinal endoscopy and fecal occult blood test in the 2007 Swiss Health Interview Survey respondents aged 50 years and older.
Spaeth A; Zwahlen M
Endoscopy; 2013 Jul; 45(7):560-6. PubMed ID: 23780844
[TBL] [Abstract][Full Text] [Related]
58. Colorectal cancer mass screening event utilising quantitative faecal occult blood test.
Chew MH; Suzanah N; Ho KS; Lim JF; Ooi BS; Tang CL; Eu KW
Singapore Med J; 2009 Apr; 50(4):348-53. PubMed ID: 19421676
[TBL] [Abstract][Full Text] [Related]
59. Evidence for colorectal cancer screening.
Bretthauer M
Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):417-25. PubMed ID: 20833346
[TBL] [Abstract][Full Text] [Related]
60. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.
Mlakar DN; Bric TK; Škrjanec AL; Krajc M
Radiol Oncol; 2018 Jul; 52(4):413-421. PubMed ID: 30511936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
